-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer
Michael Boyer, Pasi Antero Janne, Tony Mok, Kenneth OByrne, Luis Paz-Ares, Suresh S Ramalingam, Jane Liang, Ian Taylor, Alicyn Campbell, Joseph OConnell, Stephen Letrent, Vladan Antic
Methodology: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
Undue worry about paying research participants?
Christine Grady
Editorial: Clinical Investigation
-
A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma
C Lance Cowey
Review: Clinical Trail Outcomes: Clinical Investigation
-
A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma
C Lance Cowey
Review: Clinical Trail Outcomes: Clinical Investigation
-
A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma
C Lance Cowey
Review: Clinical Trail Outcomes: Clinical Investigation
-
A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma
C Lance Cowey
Review: Clinical Trail Outcomes: Clinical Investigation
-
A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma
C Lance Cowey
Review: Clinical Trail Outcomes: Clinical Investigation
-
A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma
C Lance Cowey
Review: Clinical Trail Outcomes: Clinical Investigation
-
A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma
C Lance Cowey
Review: Clinical Trail Outcomes: Clinical Investigation
-
A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma
C Lance Cowey
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Ethical issues in adult oncology randomized clinical trials
Erika P Hamilton, Jeffrey M Peppercorn
Clinical Trail Outcomes: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation
-
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
Therapeutic Prospective: Clinical Investigation